# Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis

> **NCT02029586** · PHASE2 · TERMINATED · sponsor: **Yungjin Pharm. Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver Disease

## Interventions

- **DRUG:** MB12066 200mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02029586
- **Lead sponsor:** Yungjin Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Lack of recruitment
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02029586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02029586, "Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02029586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*